Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

78 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targets of miR-200c mediate suppression of cell motility and anoikis resistance.
Howe EN, Cochrane DR, Richer JK. Howe EN, et al. Among authors: richer jk. Breast Cancer Res. 2011 Apr 18;13(2):R45. doi: 10.1186/bcr2867. Breast Cancer Res. 2011. PMID: 21501518 Free PMC article.
Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action.
Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK. Kumar NS, et al. Cancer Res. 1998 May 1;58(9):1860-5. Cancer Res. 1998. PMID: 9581825
Progesterone receptor variants found in breast cells repress transcription by wild-type receptors.
Richer JK, Lange CA, Wierman AM, Brooks KM, Tung L, Takimoto GS, Horwitz KB. Richer JK, et al. Breast Cancer Res Treat. 1998 Apr;48(3):231-41. doi: 10.1023/a:1005941117247. Breast Cancer Res Treat. 1998. PMID: 9598870
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Graham JD, et al. Among authors: richer jk. Steroids. 2000 Oct-Nov;65(10-11):579-84. doi: 10.1016/s0039-128x(00)00116-1. Steroids. 2000. PMID: 11108862 Review.
Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Graham JD, et al. Among authors: richer jk. J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):255-9. doi: 10.1016/s0960-0760(00)00101-1. J Steroid Biochem Mol Biol. 2000. PMID: 11162933 Review.
The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers.
Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB, Richer JK. Spoelstra NS, et al. Among authors: richer jk. Cancer Res. 2006 Apr 1;66(7):3893-902. doi: 10.1158/0008-5472.CAN-05-2881. Cancer Res. 2006. PMID: 16585218
Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.
Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Byron SA, et al. Among authors: richer jk. Br J Cancer. 2006 Nov 6;95(9):1220-8. doi: 10.1038/sj.bjc.6603354. Epub 2006 Oct 17. Br J Cancer. 2006. PMID: 17043687 Free PMC article.
Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.
Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Harvell DM, et al. Among authors: richer jk. Breast Cancer Res Treat. 2008 Dec;112(3):475-88. doi: 10.1007/s10549-008-9897-4. Epub 2008 Mar 9. Breast Cancer Res Treat. 2008. PMID: 18327671 Clinical Trial.
Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.
Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Harvell DM, et al. Among authors: richer jk. Breast Cancer Res Treat. 2008 Dec;112(3):489-501. doi: 10.1007/s10549-008-9923-6. Epub 2008 Mar 13. Breast Cancer Res Treat. 2008. PMID: 18338247
ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.
Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK. Singh M, et al. Among authors: richer jk. Mod Pathol. 2008 Jul;21(7):912-23. doi: 10.1038/modpathol.2008.82. Epub 2008 May 16. Mod Pathol. 2008. PMID: 18487993
78 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback